Real-world efficacy assessment for sintilimab in recurrent or metastatic cervical cancer
Sintilimab appeared to demonstrate satisfactory efficacy and safety in the study. The combination therapy showed a higher ORR compared to monotherapy. Furthermore, early initiation of sintilimab as first-line therapy within two months following recurrence is more effective compared to delayed initiation beyond this period in patients with recurrent disease.
Authors
- Ruiwei Wang
- Zhiqing Liang (ORCID: https://orcid.org/0009-0002-2994-3689)
- Kaijian Ling
- Lingjun Huang
- Dan Zhou (ORCID: https://orcid.org/0000-0001-8678-8270)
- Ping Yan (ORCID: https://orcid.org/0000-0001-9484-990X)
Institutions
- Army Medical University (CN)
- Guizhou Cancer Hospital (CN)
- Southwest Hospital (CN)
Publication Details
- Journal
- PeerJ
- Published
- 2025-12-19
- DOI
- https://doi.org/10.7717/peerj.20477
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06